TY - JOUR
T1 - Genetic engineering of microalgae for enhanced biorefinery capabilities
AU - Fayyaz, Mehmooda
AU - Chew, Kit Wayne
AU - Show, Pau Loke
AU - Ling, Tau Chuan
AU - Ng, I. Son
AU - Chang, Jo Shu
N1 - Funding Information:
This work was supported by the Fundamental Research Grant Scheme , Malaysia [ FRGS/1/2019/STG05/UNIM/02/2 ] and MyPAIR-PHC-Hibiscus Grant [ MyPAIR/1/2020/STG05/UNIM/1 ] as well as Taiwan's Ministry of Science and Technology under grant number MOST 109-3116-F-006 -016-CC1 , 108-2218-E-029-002-MY3 , 107-2221-E-006-112-MY3 , 108-2621-M-006-020 , and 108-2218-E-006-006 . This work is also supported by the RU Grant ( ST022-2019 ) and Top 100 (IIRG)-IISS Grant ( IIRG004A-19IISS ) from the University of Malaya.
Funding Information:
This work was supported by the Fundamental Research Grant Scheme, Malaysia [FRGS/1/2019/STG05/UNIM/02/2] and MyPAIR-PHC-Hibiscus Grant [MyPAIR/1/2020/STG05/UNIM/1] as well as Taiwan's Ministry of Science and Technology under grant number MOST 109-3116-F-006 -016-CC1, 108-2218-E-029-002-MY3, 107-2221-E-006-112-MY3, 108-2621-M-006-020, and 108-2218-E-006-006. This work is also supported by the RU Grant (ST022-2019) and Top 100 (IIRG)-IISS Grant (IIRG004A-19IISS) from the University of Malaya.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Microalgae-based bioproducts are in limelight because of their promising future, novel characteristics, the current situation of population needs, and rising prices of rapidly depleting energy resources. Algae-based products are considered as clean sustainable energy and food resources. At present, they are not commercialized due to their high production cost and low yield. In recent years, novel genome editing tools like RNAi, ZNFs, TALENs, and CRISPR/Cas9 are used to enhance the quality and quantity of the desired products. Genetic and metabolic engineering are frequently applied because of their rapid and precise results than random mutagenesis. Omic approaches help enhance biorefinery capabilities and are now in the developing stage for algae. The future is very bright for transgenic algae with increased biomass yield, carbon dioxide uptake rate, accumulating high-value compounds, reduction in cultivation, and production costs, thus reaching the goal in the global algal market and capital flow. However, microalgae are primary producers and any harmful exposure to the wild strains can affect the entire ecosystem. Therefore, strict regulation and monitoring are required to assess the potential risks before introducing genetically modified microalgae into the natural ecosystem.
AB - Microalgae-based bioproducts are in limelight because of their promising future, novel characteristics, the current situation of population needs, and rising prices of rapidly depleting energy resources. Algae-based products are considered as clean sustainable energy and food resources. At present, they are not commercialized due to their high production cost and low yield. In recent years, novel genome editing tools like RNAi, ZNFs, TALENs, and CRISPR/Cas9 are used to enhance the quality and quantity of the desired products. Genetic and metabolic engineering are frequently applied because of their rapid and precise results than random mutagenesis. Omic approaches help enhance biorefinery capabilities and are now in the developing stage for algae. The future is very bright for transgenic algae with increased biomass yield, carbon dioxide uptake rate, accumulating high-value compounds, reduction in cultivation, and production costs, thus reaching the goal in the global algal market and capital flow. However, microalgae are primary producers and any harmful exposure to the wild strains can affect the entire ecosystem. Therefore, strict regulation and monitoring are required to assess the potential risks before introducing genetically modified microalgae into the natural ecosystem.
UR - http://www.scopus.com/inward/record.url?scp=85084950627&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084950627&partnerID=8YFLogxK
U2 - 10.1016/j.biotechadv.2020.107554
DO - 10.1016/j.biotechadv.2020.107554
M3 - Review article
C2 - 32437732
AN - SCOPUS:85084950627
SN - 0734-9750
VL - 43
JO - Biotechnology Advances
JF - Biotechnology Advances
M1 - 107554
ER -